Developer docs
API playgroundTry for free, no card

Search company profiles

Aparito

Full company profile

uuid0002xor

Namestring
Aparito
Legal namestring
Aparito Limited
Websiteurl
aparito.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Aparito Limited is a UK-based digital health company headquartered in Wrexham, Wales, founded in 2014 by Dr. Elin Haf Davies to digitise clinical trials and capture real-world data via its Atom5™ eCOA (electronic Clinical Outcome Assessment) platform. The platform unifies video assessments, ePROs, telemedicine, eConsent, and wearable device integrations across iOS, Android, and web clients, and supports over 800 configurations with questionnaires available in 125 languages for deployment in 193 countries. Atom5™ is ISO 13485 and ISO/IEC 27001:2016 accredited and compliant with FDA 21 CFR Part 11, HIPAA, GDPR, and Cyber Essentials Plus, positioning it as sponsor-grade infrastructure for decentralised and hybrid clinical trials. The company's proprietary technology stack applies computer vision (including OpenPose-based pose estimation) and machine learning to extract objective, validated digital endpoints from patient-recorded video, with branded vCOAs including SARAhome (ataxia), vTUG (Timed Up-and-Go), vHOT, FEEDS (paediatric feeding), and DMDhome (Duchenne Muscular Dystrophy).

Aparito monetises primarily through enterprise SaaS-style study-by-study licensing of Atom5™ to pharmaceutical sponsors and CROs, supplemented by professional services from its data science team (computer vision, image/signal processing, time-series ML) and co-development engagements through the Patient Group Accelerator Programme, which partners with patient advocacy organisations (Duchenne UK, ALS Liga Belgium, International Gaucher Alliance) to develop disease-specific digital biomarkers for orphan indications. Pricing is quote-based and not publicly disclosed. The company serves pharmaceutical sponsors and CROs as its primary commercial segment, with academic clinical research groups, NHS and international hospitals, and patient advocacy groups as secondary segments. Since May 2024, Aparito has operated as a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), with the founder and all staff retained and operations continuing from Wrexham; the deal delivered a profitable exit to the Development Bank of Wales and gave Aparito embedded distribution into one of the world's largest pharmaceutical pipelines.

Short descriptiontext

Aparito provides the Atom5™ eCOA platform for decentralised clinical trials, capturing real-world data via video assessments, wearable devices, and ePROs in 125 languages across 193 countries. Founded in 2014 in Wrexham, Wales, and operating as a wholly owned subsidiary of Eli Lilly and Company since May 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWrexham, United Kingdom
HQ citystring
Wrexham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electronic clinical outcome assessments, decentralized clinical trials, digital health platform, wearable device integration, real-world data capture
Industry6 codes
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAJ
Patient App, Adherence & Engagement for RPM Programs
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Technology
Social media profiles2 records
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model4 records
1Enterprise SaaS subscription (Atom5™ eCOA platform)
TypeSubscription Recurring
Description

Aparito licenses its Atom5™ eCOA platform to pharmaceutical sponsors and CROs on a study/subscription basis, configured per protocol with over 800 platform configurations supporting global hybrid/decentralised clinical trials.

aparito.com
2Professional services & data science consulting
TypeProfessional Services
Description

Aparito's data science team provides analytical services including computer vision, image & signal processing, time series analysis and Machine Learning tooling to enhance sponsor data analysis plans and help formulate research questions.

aparito.com
3Patient Group Accelerator / co-development partnerships
TypeManaged Services
Description

Through its Patient Group Accelerator Programme, Aparito co-develops new digital biomarkers with patient organisations (e.g., DMD, PCD), generating long-tail pipeline of validated endpoints for subsequent clinical deployment.

aparito.com
4Enterprise software licensing / study configuration
TypeLicensing Royalties
Description

Study-by-study platform licensing with configuration services for sponsors running decentralised or hybrid trials, with optional provisioned devices or BYOD model.

aparito.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based enterprise licensing per study/trial
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; configured per protocol with 800+ platform configurations. Available on iOS, Android and web browser; supports BYOD or provisioned devices.

aparito.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Atom5
Description

Aparito's flagship eCOA (electronic Clinical Outcome Assessment) platform that captures patient data via Video Assessments, ePROs, Telemedicine, Wearables and eConsent, with over 800 configurations to adapt to global hybrid or decentralised study requirements.

aparito.com
+1 more record
Core offering1 text field

Aparito provides the Atom5 eCOA (electronic Clinical Outcome Assessment) platform that digitizes clinical trials by capturing patient data via video assessments, ePROs (electronic Patient-Reported Outcomes), wearable devices, telemedicine, and eConsent. The platform supports decentralized and hybrid clinical trials for pharmaceutical sponsors, CROs, and academic research groups across 193 countries and 125 languages, with over 800 configurations and compliance to FDA 21 CFR Part 11, HIPAA, GDPR, ISO 13485, and ISO 27001.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • ePRO compliance rates of 90–97% compared with ≤30% for paper PROs
+8 more records
Product overview1 text field

Aparito (a wholly owned subsidiary of Eli Lilly and Company) operates a unified decentralised clinical-trial technology stack anchored by its core Atom5™ eCOA Platform. Atom5™ is built as a platform-plus-modules architecture comprising Multi-Device Patient Data Capture, a Clinician and Sponsor Portal, an eCOA Library, and Data Management & Analytics, and supports ePROs, telemedicine, eConsent, and wearable integrations. Layered on top are video Clinical Outcome Assessment (vCOA) modules — vTUG, vHOT, SARAhome, DMDhome, and FEEDS — which use computer vision and machine learning to extract objective endpoints from patient-recorded video. Alongside this, AMP™ (Aparito Management Platform) provides an electronic Quality Management System (eQMS), and the Patient Group Accelerator Programme supports rare disease patient groups. The portfolio is positioned as a regulated, patient-centric decentralised trial platform (FDA 21 CFR Part 11, HIPAA, GDPR, ISO 27001, ISO 13485, Cyber Essentials Plus).

Product and service4 records
1Atom5 eCOA Platform
CategoryCore Platform
2AMP (Aparito Management Platform)
CategorySub-product / eQMS
3Patient Group Accelerator Programme
CategoryService Offering
4Professional Services & Data Science Consulting
CategoryService Offering
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierResearch CollaboratorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnered on the PRiORiTy Usability Study — recruiting individuals with traumatic brain injury for usability testing of the Atom5™ ePRO platform via 'Think Aloud' cognitive interviews.

Strategic tierFlagship / Parent CompanyTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

In May 2024, US-based pharmaceutical company Eli Lilly and Company acquired UK-based Aparito Limited to strengthen capabilities in decentralised clinical trials and patient-centric data collection. Founder Dr Elin Haf Davies and all staff retained; Aparito continues to operate from Wrexham, Wales, as a wholly owned subsidiary of Eli Lilly. The partnership gives Aparito global distribution reach across Eli Lilly's pharmaceutical pipeline.

3PROFA Study consortium (Friedreich ataxia centres in Germany, France, Austria)
Strategic tierMid-Tier Research PartnerTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Pan-European observational study (n=200) deploying SARAhome via the Atom5™ eCOA platform across six study centres in Germany, France and Austria to capture patient-reported, health economic and psychosocial outcomes in Friedreich ataxia.

aparito.com
4ALS Liga Belgium
Strategic tierStrategic (Patient Group Accelerator)TypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Aparito's Patient Group Accelerator and ALS Liga Belgium have collaborated to develop digital endpoints capturing meaningful aspects of health (MAH), concepts of interest (COI), and outcomes for ALS patients. Co-developed ALSHome digital outcome measures are tested for usability and clinical utility on the Atom5™ platform.

aparito.com
5International Gaucher Alliance (IGA)
Strategic tierStrategic (Patient Group Accelerator)TypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Co-developed GaRDIAN — the patient-led, patient-owned registry for neuronopathic Gaucher disease (nGD) — with Aparito's Elin Haf Davies as a key architect. The registry collects disease-specific patient-reported and observer-reported outcomes to inform regulatory real-world data needs.

aparito.com
6Long COVID SOS / Long COVID Scotland / Long COVID Support
Strategic tierPatient Advocacy CollaboratorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Patient and public involvement and engagement (PPIE) partners who assisted with recruitment of study participants for the TLC Study using Atom5™ ePRO/eConsent, supporting the Nature Medicine publication on PPIE considerations.

aparito.com
Strategic tierCore ScientificTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Co-developed SARAhome — the video-based version of the Scale for the Assessment and Rating of Ataxia — with Dr Marcus Grobe-Einsler and team at DZNE. Validated in 526 spinocerebellar ataxia patients from EUROSCA, with the deployment also powered by machine-learning-based automatic speech rating.

Strategic tierCore StrategicTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Aparito partners with the Centre for Patient Reported Outcome Research (CPROR) at the University of Birmingham to co-develop digital PROs for a wide range of disease groups, configure Atom5™ for patient quality-of-life and symptom assessment in clinical trials and routine NHS care, and inform regulators (MHRA) and policymakers (NICE). Joint work includes the Symptom Burden Questionnaire™ for Long COVID (TLC Study) and the ATMP basket trial ePRO (PROmics).

Strategic tierMid-Tier Research PartnerTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Joint research exploring the role of video recording and analysis in rare disease drug development, including use of video in the development of asfotase alfa (Strensiq®) in hypophosphatasia and the development of SARAhome for ataxia. Co-authored the 'Time to See the Difference: Video Capture for Patient-Centered Clinical Trials' paper in The Patient journal.

Strategic tierResearch CollaboratorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Joint feasibility study demonstrating mHealth technology potential to improve management of paediatric epilepsy in resource-limited South African settings, using the Atom5™ platform.

Strategic tierCore StrategicTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Aparito co-developed the DMDhome video-based approach with Duchenne UK, delivered through the Atom5™ platform, to assess motor function in patients with Duchenne Muscular Dystrophy. Pioneering work in computer vision analysis (OpenPose) of upper and lower limb function. Duchenne UK was one of the first two patient groups selected for Aparito's Patient Group Accelerator Programme.

12PCD Support UK (Primary Ciliary Dyskinesia)
Strategic tierPatient Group Accelerator PartnerTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

One of the first two patient groups selected for Aparito's Patient Group Accelerator Programme alongside Duchenne UK, focused on developing digital endpoints and biomarkers for PCD.

aparito.com
Strategic tierTechnology Integration LayerTypeTechnology or Integration
Description

Atom5™ integrates with any device that has an available API/SDK, including commercial-grade wearables such as the Garmin Venu 2 used in the digital 1-Minute Walk Test (1MWT) pilot study for pulmonary hypertension.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medidata (a Dassault Systèmes company) is a leading eCOA and eClinical platform vendor serving the same pharmaceutical sponsors and CROs as Aparito. Its Rave eCOA suite is the most widely deployed direct competitor to Atom5™ in regulated clinical trials.

TypeDirect peer
Description

Clario (formed by the merger of ERT and Bioclinica) is a major eCOA and clinical endpoint technology vendor offering electronic patient-reported outcomes, wearables and decentralised trial solutions directly competitive with Aparito's Atom5™ platform.

TypeDirect peer
Description

Signant Health (formed from CRF Health and Bracket) provides eCOA, ePRO, rater training and patient engagement solutions for global clinical trials. Its eCOA platform directly competes with Aparito's Atom5™ for sponsor study wins.

4Oracle Health Sciences (Clinical One / Phase Forward)
TypeBroad incumbent
Description

Oracle Health Sciences offers Clinical One eClinical platform and the legacy Phase Forward eCOA suite, serving large pharmaceutical sponsors with broader eClinical workflows in which eCOA is one component — a broad incumbent competing for the same sponsor budgets as Aparito.

TypeBroad incumbent
Description

Veeva provides Vault eClinical, CTMS and CDB platforms to life sciences sponsors and CROs. While not eCOA-native, Vault competes with Atom5™ for sponsor platform budget and decentralised trial orchestration.

TypeDirect peer
Description

Science 37 is a decentralised clinical trial operating model and platform competitor to Aparito, focused on enabling at-home patient participation in sponsor trials with similar eCOA, telemedicine and wearable capabilities.

TypeEmerging player
Description

Medable offers a decentralised and hybrid clinical trial platform with eCOA, eConsent, telehealth and wearable integration — competing with Atom5™ for sponsor and CRO DCT deployments, particularly among emerging biopharma sponsors.

TypeEmerging player
Description

Castor provides an eClinical platform with ePRO and decentralised trial capabilities aimed at academic and biotech sponsors. It overlaps with Aparito's Atom5™ in ePRO and patient data capture but lacks Aparito's validated video COA library.

TypeDirect peer
Description

ObvioHealth runs fully decentralised clinical trials using its own eCOA platform with wearables, ePRO and remote monitoring — directly comparable to Aparito's Atom5™-enabled DCT offering for pharma sponsors.

TypeEmerging player
Description

Koneksa Health develops digital biomarkers and wearable-derived endpoints for clinical trials, overlapping with Aparito's computer-vision and wearable analytics capabilities within Atom5™, particularly in neuroscience and rare disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aparito

Clinical Trial Technologyaparito.com

Aparito provides the Atom5™ eCOA platform for decentralised clinical trials, capturing real-world data via video assessments, wearable devices, and ePROs in 125 languages across 193 countries. Founded in 2014 in Wrexham, Wales, and operating as a wholly owned subsidiary of Eli Lilly and Company since May 2024.

What Aparito does

Aparito Limited is a UK-based digital health company headquartered in Wrexham, Wales, founded in 2014 by Dr. Elin Haf Davies to digitise clinical trials and capture real-world data via its Atom5™ eCOA (electronic Clinical Outcome Assessment) platform. The platform unifies video assessments, ePROs, telemedicine, eConsent, and wearable device integrations across iOS, Android, and web clients, and supports over 800 configurations with questionnaires available in 125 languages for deployment in 193 countries. Atom5™ is ISO 13485 and ISO/IEC 27001:2016 accredited and compliant with FDA 21 CFR Part 11, HIPAA, GDPR, and Cyber Essentials Plus, positioning it as sponsor-grade infrastructure for decentralised and hybrid clinical trials. The company's proprietary technology stack applies computer vision (including OpenPose-based pose estimation) and machine learning to extract objective, validated digital endpoints from patient-recorded video, with branded vCOAs including SARAhome (ataxia), vTUG (Timed Up-and-Go), vHOT, FEEDS (paediatric feeding), and DMDhome (Duchenne Muscular Dystrophy).

Aparito monetises primarily through enterprise SaaS-style study-by-study licensing of Atom5™ to pharmaceutical sponsors and CROs, supplemented by professional services from its data science team (computer vision, image/signal processing, time-series ML) and co-development engagements through the Patient Group Accelerator Programme, which partners with patient advocacy organisations (Duchenne UK, ALS Liga Belgium, International Gaucher Alliance) to develop disease-specific digital biomarkers for orphan indications. Pricing is quote-based and not publicly disclosed. The company serves pharmaceutical sponsors and CROs as its primary commercial segment, with academic clinical research groups, NHS and international hospitals, and patient advocacy groups as secondary segments. Since May 2024, Aparito has operated as a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), with the founder and all staff retained and operations continuing from Wrexham; the deal delivered a profitable exit to the Development Bank of Wales and gave Aparito embedded distribution into one of the world's largest pharmaceutical pipelines.

Aparito firmographics

Firmographics
Name
Aparito
Legal name
Aparito Limited
Website
https://aparito.com
Company type
Private
Founded year
2014
Operating status
Acquired
Headcount range
11–50 employees
Short description
Aparito provides the Atom5™ eCOA platform for decentralised clinical trials, capturing real-world data via video assessments, wearable devices, and ePROs in 125 languages across 193 countries. Founded in 2014 in Wrexham, Wales, and operating as a wholly owned subsidiary of Eli Lilly and Company since May 2024.
Ownership category
akta.pro rank

Aparito industry classification

Industry
Product category
Clinical Trial Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAA
Electronic Data Capture (EDC) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAJ
Patient App, Adherence & Engagement for RPM Programs
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAIAD
ePrescribing & Medication Workflow Platforms (EPCS, formulary, prior auth, med history)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Electronic clinical outcome assessments
  • Decentralized clinical trials
  • Digital health platform
  • Wearable device integration
  • Real-world data capture

Where Aparito is headquartered

Location

Headquarters

HQ city
Wrexham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Aparito business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Enterprise SaaS subscription (Atom5™ eCOA platform): Aparito licenses its Atom5™ eCOA platform to pharmaceutical sponsors and CROs on a study/subscription basis, configured per protocol with over 800 platform configurations supporting global hybrid/decentralised clinical trials.
  2. Professional services & data science consulting: Aparito's data science team provides analytical services including computer vision, image & signal processing, time series analysis and Machine Learning tooling to enhance sponsor data analysis plans and help formulate research questions.
  3. Patient Group Accelerator / co-development partnerships: Through its Patient Group Accelerator Programme, Aparito co-develops new digital biomarkers with patient organisations (e.g., DMD, PCD), generating long-tail pipeline of validated endpoints for subsequent clinical deployment.
  4. Enterprise software licensing / study configuration: Study-by-study platform licensing with configuration services for sponsors running decentralised or hybrid trials, with optional provisioned devices or BYOD model.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise licensing per study/trial

Go-to-market motion5 records

Distribution channels4 records

Marketing channels7 records

Aparito product offering

Product offering

Core offering

Aparito provides the Atom5 eCOA (electronic Clinical Outcome Assessment) platform that digitizes clinical trials by capturing patient data via video assessments, ePROs (electronic Patient-Reported Outcomes), wearable devices, telemedicine, and eConsent. The platform supports decentralized and hybrid clinical trials for pharmaceutical sponsors, CROs, and academic research groups across 193 countries and 125 languages, with over 800 configurations and compliance to FDA 21 CFR Part 11, HIPAA, GDPR, ISO 13485, and ISO 27001.

Product overview

Aparito (a wholly owned subsidiary of Eli Lilly and Company) operates a unified decentralised clinical-trial technology stack anchored by its core Atom5™ eCOA Platform. Atom5™ is built as a platform-plus-modules architecture comprising Multi-Device Patient Data Capture, a Clinician and Sponsor Portal, an eCOA Library, and Data Management & Analytics, and supports ePROs, telemedicine, eConsent, and wearable integrations. Layered on top are video Clinical Outcome Assessment (vCOA) modules — vTUG, vHOT, SARAhome, DMDhome, and FEEDS — which use computer vision and machine learning to extract objective endpoints from patient-recorded video. Alongside this, AMP™ (Aparito Management Platform) provides an electronic Quality Management System (eQMS), and the Patient Group Accelerator Programme supports rare disease patient groups. The portfolio is positioned as a regulated, patient-centric decentralised trial platform (FDA 21 CFR Part 11, HIPAA, GDPR, ISO 27001, ISO 13485, Cyber Essentials Plus).

Differentiator

Problem solved

Functional benefit

Brands

  • Atom5: Aparito's flagship eCOA (electronic Clinical Outcome Assessment) platform that captures patient data via Video Assessments, ePROs, Telemedicine, Wearables and eConsent, with over 800 configurations to adapt to global hybrid or decentralised study requirements.
  • AMP (Aparito Management Platform)

Products and services

  • Atom5 eCOA Platform
  • AMP (Aparito Management Platform)
  • Patient Group Accelerator Programme
  • Professional Services & Data Science Consulting

Quantifiable outcome

  • ePRO compliance rates of 90–97% compared with ≤30% for paper PROs
  • +8 more outcomes

Companies that use Aparito

Customer profile

Named customers14 records

Segments6 records

Ideal customer profiles4 records

Aparito technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability9 records

Feature11 records

Aparito partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered research collaborator, flagship / parent company, mid-tier research partner, strategic (patient group accelerator), patient advocacy collaborator, core scientific, core strategic, patient group accelerator partner and technology integration layer.

  • Headway UKresearch collaboratorStrategic or Co-development Partner · 1 January 2025Partnered on the PRiORiTy Usability Study — recruiting individuals with traumatic brain injury for usability testing of the Atom5™ ePRO platform via 'Think Aloud' cognitive interviews.
  • Eli Lilly and Companyflagship / parent companyStrategic or Co-development Partner · 1 May 2024In May 2024, US-based pharmaceutical company Eli Lilly and Company acquired UK-based Aparito Limited to strengthen capabilities in decentralised clinical trials and patient-centric data collection. Founder Dr Elin Haf Davies and all staff retained; Aparito continues to operate from Wrexham, Wales, as a wholly owned subsidiary of Eli Lilly. The partnership gives Aparito global distribution reach across Eli Lilly's pharmaceutical pipeline.
  • PROFA Study consortium (Friedreich ataxia centres in Germany, France, Austria)mid-tier research partnerStrategic or Co-development Partner · 1 August 2023Pan-European observational study (n=200) deploying SARAhome via the Atom5™ eCOA platform across six study centres in Germany, France and Austria to capture patient-reported, health economic and psychosocial outcomes in Friedreich ataxia.
  • ALS Liga Belgiumstrategic (patient group accelerator)Strategic or Co-development Partner · 1 January 2023Aparito's Patient Group Accelerator and ALS Liga Belgium have collaborated to develop digital endpoints capturing meaningful aspects of health (MAH), concepts of interest (COI), and outcomes for ALS patients. Co-developed ALSHome digital outcome measures are tested for usability and clinical utility on the Atom5™ platform.
  • International Gaucher Alliance (IGA)strategic (patient group accelerator)Strategic or Co-development Partner · 1 January 2023Co-developed GaRDIAN — the patient-led, patient-owned registry for neuronopathic Gaucher disease (nGD) — with Aparito's Elin Haf Davies as a key architect. The registry collects disease-specific patient-reported and observer-reported outcomes to inform regulatory real-world data needs.
  • Long COVID SOS / Long COVID Scotland / Long COVID Supportpatient advocacy collaboratorStrategic or Co-development Partner · 1 January 2023Patient and public involvement and engagement (PPIE) partners who assisted with recruitment of study participants for the TLC Study using Atom5™ ePRO/eConsent, supporting the Nature Medicine publication on PPIE considerations.
  • DZNE (Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.)core scientificStrategic or Co-development Partner · 1 June 2022Co-developed SARAhome — the video-based version of the Scale for the Assessment and Rating of Ataxia — with Dr Marcus Grobe-Einsler and team at DZNE. Validated in 526 spinocerebellar ataxia patients from EUROSCA, with the deployment also powered by machine-learning-based automatic speech rating.
  • University of Birmingham (CPROR)core strategicStrategic or Co-development Partner · 1 January 2022Aparito partners with the Centre for Patient Reported Outcome Research (CPROR) at the University of Birmingham to co-develop digital PROs for a wide range of disease groups, configure Atom5™ for patient quality-of-life and symptom assessment in clinical trials and routine NHS care, and inform regulators (MHRA) and policymakers (NICE). Joint work includes the Symptom Burden Questionnaire™ for Long COVID (TLC Study) and the ATMP basket trial ePRO (PROmics).
  • Alexion, AstraZeneca Rare Diseasemid-tier research partnerStrategic or Co-development Partner · 1 January 2022Joint research exploring the role of video recording and analysis in rare disease drug development, including use of video in the development of asfotase alfa (Strensiq®) in hypophosphatasia and the development of SARAhome for ataxia. Co-authored the 'Time to See the Difference: Video Capture for Patient-Centered Clinical Trials' paper in The Patient journal.
  • Red Cross War Memorial Children's Hospital & University of Cape Town (epilepsy / mHealth study)research collaboratorStrategic or Co-development Partner · 1 January 2022Joint feasibility study demonstrating mHealth technology potential to improve management of paediatric epilepsy in resource-limited South African settings, using the Atom5™ platform.
  • Duchenne UKcore strategicStrategic or Co-development Partner · 1 January 2020Aparito co-developed the DMDhome video-based approach with Duchenne UK, delivered through the Atom5™ platform, to assess motor function in patients with Duchenne Muscular Dystrophy. Pioneering work in computer vision analysis (OpenPose) of upper and lower limb function. Duchenne UK was one of the first two patient groups selected for Aparito's Patient Group Accelerator Programme.
  • PCD Support UK (Primary Ciliary Dyskinesia)patient group accelerator partnerStrategic or Co-development Partner · 1 January 2020One of the first two patient groups selected for Aparito's Patient Group Accelerator Programme alongside Duchenne UK, focused on developing digital endpoints and biomarkers for PCD.
  • Wearable device manufacturers (integrated via API/SDK)technology integration layerTechnology or IntegrationAtom5™ integrates with any device that has an available API/SDK, including commercial-grade wearables such as the Garmin Venu 2 used in the digital 1-Minute Walk Test (1MWT) pilot study for pulmonary hypertension.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Aparito competitors and assessment

Company assessment

Direct peers

  • Medidata Solutions: Medidata (a Dassault Systèmes company) is a leading eCOA and eClinical platform vendor serving the same pharmaceutical sponsors and CROs as Aparito. Its Rave eCOA suite is the most widely deployed direct competitor to Atom5™ in regulated clinical trials.
  • Clario: Clario (formed by the merger of ERT and Bioclinica) is a major eCOA and clinical endpoint technology vendor offering electronic patient-reported outcomes, wearables and decentralised trial solutions directly competitive with Aparito's Atom5™ platform.
  • Signant Health: Signant Health (formed from CRF Health and Bracket) provides eCOA, ePRO, rater training and patient engagement solutions for global clinical trials. Its eCOA platform directly competes with Aparito's Atom5™ for sponsor study wins.
  • Science 37: Science 37 is a decentralised clinical trial operating model and platform competitor to Aparito, focused on enabling at-home patient participation in sponsor trials with similar eCOA, telemedicine and wearable capabilities.
  • ObvioHealth: ObvioHealth runs fully decentralised clinical trials using its own eCOA platform with wearables, ePRO and remote monitoring — directly comparable to Aparito's Atom5™-enabled DCT offering for pharma sponsors.

Broad incumbents

  • Oracle Health Sciences (Clinical One / Phase Forward): Oracle Health Sciences offers Clinical One eClinical platform and the legacy Phase Forward eCOA suite, serving large pharmaceutical sponsors with broader eClinical workflows in which eCOA is one component — a broad incumbent competing for the same sponsor budgets as Aparito.
  • Veeva Systems: Veeva provides Vault eClinical, CTMS and CDB platforms to life sciences sponsors and CROs. While not eCOA-native, Vault competes with Atom5™ for sponsor platform budget and decentralised trial orchestration.

Emerging players

  • Medable: Medable offers a decentralised and hybrid clinical trial platform with eCOA, eConsent, telehealth and wearable integration — competing with Atom5™ for sponsor and CRO DCT deployments, particularly among emerging biopharma sponsors.
  • Castor: Castor provides an eClinical platform with ePRO and decentralised trial capabilities aimed at academic and biotech sponsors. It overlaps with Aparito's Atom5™ in ePRO and patient data capture but lacks Aparito's validated video COA library.
  • Koneksa Health: Koneksa Health develops digital biomarkers and wearable-derived endpoints for clinical trials, overlapping with Aparito's computer-vision and wearable analytics capabilities within Atom5™, particularly in neuroscience and rare disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Aparito social profiles

Digital presence

Aparito compliance and trust

Trust signal

Compliance6 records

Aparito financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aparito leadership team

Management profile

Number of profiles

Profiles3 records

Aparito funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aparito M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aparito

What does Aparito do?

Aparito provides the Atom5 eCOA (electronic Clinical Outcome Assessment) platform that digitizes clinical trials by capturing patient data via video assessments, ePROs (electronic Patient-Reported Outcomes), wearable devices, telemedicine, and eConsent. The platform supports decentralized and hybrid clinical trials for pharmaceutical sponsors, CROs, and academic research groups across 193 countries and 125 languages, with over 800 configurations and compliance to FDA 21 CFR Part 11, HIPAA, GDPR, ISO 13485, and ISO 27001.

Is Aparito a public or private company?

Aparito is a private company. It is classified as corporate owned and is currently acquired.

When was Aparito founded?

Aparito was founded in 2014. It employs 11 to 50 people.

Where is Aparito based?

Aparito is headquartered in Wrexham, United Kingdom, in the Europe region.

How does Aparito make money?

Four revenue lines are on record. Enterprise SaaS subscription (Atom5™ eCOA platform) is the primary driver. The others are professional services & data science consulting, patient Group Accelerator / co-development partnerships and enterprise software licensing / study configuration.

Who are Aparito's main competitors?

Direct peers on record are Medidata Solutions, Clario, Signant Health, Science 37 and ObvioHealth. Broad incumbents are Oracle Health Sciences (Clinical One / Phase Forward) and Veeva Systems. Emerging players are Medable, Castor and Koneksa Health.

Does Aparito have an API?

Yes. Atom5™ integrates with any device that has an available API/SDK, such as wearable or medical devices. The platform can also integrate with other Electronic Data Capture (EDC) systems or provide raw data exports in custom formats. No public developer-facing documentation URL was specified in the source material.

What industry is Aparito in?

Aparito's product category is Clinical Trial Technology. Its primary akta.pro industry code is HLACAOAA, Electronic Data Capture (EDC) Platforms, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business LiveNorth Wales has never lacked assets or ambition, but what is changing now is the scale of opportunityGiles Thorley, CEO of the Development Bank of Wales, argues North Wales faces a new phase of growth driven by major investment programmes. He highlights opportunities in energy, manufacturing, and tourism, while noting productivity and skills gaps remain below UK averages. The region's growth must be place-based and inclusive to be sustained.openPR.comOutlook on the Electronic Patient-Reported Outcomes (ePRO) Analytics Market Using Artificial Intelligence (AI): Major Segments, Strategic Developments, and Leading CompaniesThe global electronic patient-reported outcomes analytics market enhanced by AI is projected to reach $3.74 billion by 2030, growing at a compound annual growth rate of 15.4%, driven by increasing AI adoption in clinical research, demand for continuous patient monitoring, and expansion of decentralized clinical trials. In May 2024, US-based pharmaceutical company Eli Lilly and Company acquired UK-based Aparito Limited, a specialist in ePRO and AI-driven digital health solutions, to strengthen its capabilities in decentralized clinical trials and patient-centric data collection. The market report identifies key players including Oracle Health Sciences, IQVIA Inc., Parexel International Corporation, and Veeva Systems Inc., while providing detailed segmentation across components, applications, deployment models, and end-users.outsourcing-pharma.comInvestors and big pharma no longer avoiding techbio companiesBig pharma and investors are increasingly engaging with techbio companies, as seen in Eli Lilly's acquisition of Aparito. Panelists note that techbio startups now attract capital, though licensing deals take 12-18 months and business models vary. Founders are advised to focus on deliverables and consider non-traditional investors.Life Sciences SolutionsOracle Life SciencesOracle Life Sciences provides cloud-based solutions and research services for sponsors, CROs, and research sites, with embedded AI and analytics. The company promotes its platform for streamlining operations and accelerating study design, and announces its 2026 Health and Life Sciences Summit in Orlando, Florida, for September 20–22, 2027.We're Bethnal Green VenturesInvesting in Healthy LivesBGV highlights the UK HealthTech sector's £25.6bn turnover and its focus on prevention-focused startups. It profiles Second Nature, Aparito, and TalkLife, noting Second Nature's 79% completion rate and 8.3% average weight loss, and TalkLife's 1.5 million users across 125 countries.